Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial

Blood (2023) 142 (Supplement 1): 76.

https://doi.org/10.1182/blood-2023-188904

Published: 2023

Journal Articles

AZURE: A Phase 1/2 Study of Blu-263 As Monotherapy and in Combination with Azacitidine in Patients with Advanced Systemic Mastocytosis

Daniel J. DeAngelo, Andreas Reiter, Tracy I. George, Deepti H. Radia, Marissa Devlin, Saša Dimitrijević, Mikael Rinne, Robyn Scherber, Jason Gotlib

Blood (2022) 140 (Supplement 1): 6877–6878.

https://doi.org/10.1182/blood-2022-167410

Published: 2022

Journal Articles

Community Versus Academic Practice in Essential Thrombocythemia and Myelofibrosis: Differences in Clinical Characteristics, Diagnosis, Treatment Patterns, and Symptom Burden (Analysis of Data from the MOST Study)

Roger Lyons, David Lessen, Salman Fazal, Robyn Scherber, Patricia Kalafut, Haobo Ren, Ellen Ritchie

Blood (2021) 138 (Supplement 1): 1497.

https://doi.org/10.1182/blood-2021-145909

Published: 2021

Journal Articles

Exploring Genotype:Phenotype Correlations at Baseline and at One Year for ET and PV Patients in the Majic Study

Chandan Saha, Carolyn Mead-Harvey, Adam J. Mead, Rebecca H. Boucher, Sonia Fox, Isaak Ailts, Christina Yap, Aimee E Jackson, Joanne Ewing, Jason Coppell, Steve Knapper, Mark W. Drummond, Anna L Godfrey, Amylou C. Dueck, Ruben A. Mesa, Robyn Scherber, Mary Frances McMullin, Holly L. Geyer, Claire N. Harrison

Blood (2021) 138 (Supplement 1): 1507.

https://doi.org/10.1182/blood-2021-151568

Published: 2021

Journal Articles

Does Early Intervention in Myelofibrosis Impact Outcomes? a Pooled Analysis of the Comfort I and II Studies

Srdan Verstovsek, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Ruben A. Mesa, Robyn Scherber, J.E. Hamer-Maansson, Claire N. Harrison

Blood (2021) 138 (Supplement 1): 1505.

https://doi.org/10.1182/blood-2021-150894

Published: 2021

Journal Articles

Correlation of Quality of Life between Treatment Outcomes in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Polycythemia Vera

Isaak Ailts, Carolyn Mead-Harvey, Adam J. Mead, Sonia Fox, Rebecca H. Boucher, Christina Yap, Chandan Saha, Robyn Scherber, Aimee Jackson, Joanne Ewing, Jason Coppell, Steve Knapper, Mark W. Drummond, Anna L Godfrey, Amylou C. Dueck, Mary Frances McMullin, Ruben A. Mesa, Claire N. Harrison, Holly L. Geyer

Blood (2021) 138 (Supplement 1): 3644.

https://doi.org/10.1182/blood-2021-147637

Published: 2021

Journal Articles

A Real-World Evaluation of the Association between Elevated Blood Counts and Thrombotic Events in Polycythemia Vera (Analysis of Data from the REVEAL Study)

Aaron T. Gerds, Ruben A. Mesa, John M. Burke, Michael R. Grunwald, Brady Lee Stein, Robyn Scherber, Jingbo Yu, J.E. Hamer-Maansson, Stephen Oh

Blood (2021) 138 (Supplement 1): 239.

https://doi.org/10.1182/blood-2021-148509

Published: 2021

Journal Articles

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide

Blood (2017) 130 (17): 1889–1897.

https://doi.org/10.1182/blood-2017-05-785790

Published: 2017

Includes: Supplemental data

Journal Articles

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

Rami S. Komrokji, John F. Seymour, Andrew W. Roberts, Martha Wadleigh, L. Bik To, Robyn Scherber, Elyce Turba, Andrew Dorr, Joy Zhu, Lixia Wang, Tanya Granston, Mary S. Campbell, Ruben A. Mesa

Blood (2015) 125 (17): 2649–2655.

https://doi.org/10.1182/blood-2013-02-484832

Published: 2015

Includes: Supplemental data

Journal Articles

The Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs),

Robyn Scherber, MPH, Medical-Student, Amylou Dueck, PhD, Jean-Jacques Kiladjian, MD, PhD, Stephanie Slot, BSc, Sonja Zweegman, MD, PhD, Peter te Boekhorst, MD, PhD, Suzan Commandeur, MSc, Harry C. Schouten, MD, PhD, Federico Sackmann, Ana Kerguelen Fuentes, MD, Dolores Hernandez-Maraver, PhD, Heike L. Pahl, PhD, Martin Griesshammer, MD, Frank Stegelmann, MD, Konstanze Doehner, Prof., Thomas Lehmann, MD, Karin Bonatz, MD, Andreas Reiter, MD, Françoise Boyer, MD, Gabriel Etienne, MD, PhD, Jean-Christophe Ianotto, MD, Dana Ranta, MD, Lydia Roy, Jean-Yves Cahn, MD, Claire N. Harrison, DM, FRCP, FRCPath, Deepti Radia, MD, Pablo J. Muxi, MD, Norman I Maldonado, MD, Carlos Besses, MD, PhD, Francisco Cervantes, MD, Peter Johansson, MD, PhD, Tiziano Barbui, MD, Giovanni Barosi, MD, Alessandro M. Vannucchi, MD, Francesco Passamonti, MD, Bjorn Andreasson, MD, Maria L Ferarri, MD, Alessandro Rambaldi, Jan Samuelsson, MD, PhD, Gunnar Birgegard, MD, PhD, Ayalew Tefferi, MD, Ruben A. Mesa, MD

Blood (2011) 118 (21): 3839.

https://doi.org/10.1182/blood.V118.21.3839.3839

Published: 2011

Journal Articles

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

Robyn Scherber, Amylou C. Dueck, Peter Johansson, Tiziano Barbui, Giovanni Barosi, Alessandro M. Vannucchi, Francesco Passamonti, Bjorn Andreasson, Maria L. Ferarri, Alessandro Rambaldi, Jan Samuelsson, Gunnar Birgegard, Ayalew Tefferi, Claire N. Harrison, Deepti Radia, Ruben A. Mesa

Blood (2011) 118 (2): 401–408.

https://doi.org/10.1182/blood-2011-01-328955

Published: 2011

Journal Articles

Prospective Validation of the Swedish Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Swedish) In 114 MPN Patients

Peter L. Johansson, MD, PhD, Bjorn Andreasson, MD, Robyn Scherber, MPH, Medical-Student, Amylou Dueck, PhD, Jan Samuelsson, MD, PhD, Gunnar Birgegard, MD, PhD, Ayalew Tefferi, MD, Ruben A. Mesa, MD

Blood (2010) 116 (21): 5053.

https://doi.org/10.1182/blood.V116.21.5053.5053

Published: 2010

Journal Articles

Prospective Validation of the Italian Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Italian) In 186 MPN Patients

Robyn Scherber, MPH, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD, Francesco Passamonti, MD, Giovanni Barosi, MD, Alessandro Rambaldi, MD, Maria L Ferarri, MD, Amylou Dueck, PhD, Ayalew Tefferi, MD, Ruben A. Mesa, MD

Blood (2010) 116 (21): 5060.

https://doi.org/10.1182/blood.V116.21.5060.5060

Published: 2010

Journal Articles

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): An International Prospective Validation Trial In 402 Patients

Robyn Scherber, MPH, Medical-Student, Amylou Dueck, PhD, Peter L. Johansson, MD, PhD, Tiziano Barbui, MD, Giovanni Barosi, MD, Alessandro M. Vannucchi, MD, Francesco Passamonti, Bjorn Andreasson, MD, PhD, Maria L Ferarri, MD, Alessandro Rambaldi, MD, Jan Samuelsson, MD, PhD, Gunnar Birgegard, MD, PhD, Ayalew Tefferi, MD, Claire N. Harrison, DM, Deepti Radia, Ruben A. Mesa, MD

Blood (2010) 116 (21): 4095.

https://doi.org/10.1182/blood.V116.21.4095.4095

Published: 2010

NARROW

Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial

AZURE: A Phase 1/2 Study of Blu-263 As Monotherapy and in Combination with Azacitidine in Patients with Advanced Systemic Mastocytosis

Community Versus Academic Practice in Essential Thrombocythemia and Myelofibrosis: Differences in Clinical Characteristics, Diagnosis, Treatment Patterns, and Symptom Burden (Analysis of Data from the MOST Study)

Exploring Genotype:Phenotype Correlations at Baseline and at One Year for ET and PV Patients in the Majic Study

Does Early Intervention in Myelofibrosis Impact Outcomes? a Pooled Analysis of the Comfort I and II Studies

Correlation of Quality of Life between Treatment Outcomes in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Polycythemia Vera

A Real-World Evaluation of the Association between Elevated Blood Counts and Thrombotic Events in Polycythemia Vera (Analysis of Data from the REVEAL Study)

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

The Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs),

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

Prospective Validation of the Swedish Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Swedish) In 114 MPN Patients

Prospective Validation of the Italian Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Italian) In 186 MPN Patients

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): An International Prospective Validation Trial In 402 Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only